IRDye800CW-nimotuzumab

N/A

Report date: 2023/01/01 08:31:39

Base Information

Drug NameIRDye800CW-nimotuzumab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugateDiagnostic agent (In vivo) > Contrast agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDiagnostic imaging enhancers

TargetsNot applicable

Therapy Area/IndicationsContrast agentsLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Saskatchewan

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Saskatchewan

Inactive CompaniesN/A

Active IndicationsContrast agentsLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A